Amgen (AMGN) Received its Third Buy in a Row


According to TipRanks.com, Olson is a 1-star analyst with an average return of -1.7% and a 39.9% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $266.50, which is a 16.1% upside from current levels. In a report issued on October 8, Piper Sandler also maintained a Buy rating on the stock with a $270.00 price target.

See today’s analyst top recommended stocks >>

Amgen’s market cap is currently $135.4B and has a P/E ratio of 18.80. The company has a Price to Book ratio of -6.15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts